HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review

J Carlsson, H Nordgren, J Sjöström, K Wester, K Villman, N O Bengtsson, B Ostenstad, H Lundqvist, C Blomqvist, J Carlsson, H Nordgren, J Sjöström, K Wester, K Villman, N O Bengtsson, B Ostenstad, H Lundqvist, C Blomqvist

Abstract

The aim of this study was to evaluate whether the HER2 expression in breast cancer is retained in metastases. The HER2 expression in primary tumours and the corresponding lymph node metastases were evaluated in parallel samples from 47 patients. The HercepTest was used for immunohistochemical analyses of HER2 overexpression in all cases. CISH/FISH was used for analysis of gene amplification in some cases. HER2 overexpression (HER2-scores 2+ or 3+) was found in 55% of both the primary tumours and of the lymph node metastases. There were only small changes in the HER2-scores; six from 1+ to 0 and one from 3+ to 2+ when the metastases were compared to the corresponding primary tumours. However, there were no cases with drastic changes in HER2 expression between the primary tumours and the corresponding lymph node metastases. The literature was reviewed for similar investigations, and it is concluded that breast cancer lymph node metastases generally overexpress HER2 to the same extent as the corresponding primary tumours. This also seems to be the case when distant metastases are considered. It has been noted that not all patients with HER2 overexpression respond to HER2-targeted Trastuzumab treatment. The stability in HER2 expression is encouraging for efforts to develop complementary forms of therapy, for example, therapy with radionuclide-labelled Trastuzumab.

Figures

Figure 1
Figure 1
Typical immunohistochemical HER2-stainings. A section from a primary breast tumour (A) and a section of a lymph node metastasis (B) from the same patient are shown. Both cases were scored 3+.

References

    1. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61: 4750–4755
    1. Ahmed NU, Ueda M, Ichihashi M (1997) Increased level of c-erbB-2/neu/HER-2 protein in cutaneous squamous cell carcinoma. Br J Dermatol 136: 908–912
    1. Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L, Pettersson-Skold D, Sverrisdottir A, Soderberg M, Klaar S, Bergh J (2002) A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden. Acta Oncol 41: 276–281
    1. Bertram JS (2000) The molecular biology of cancer. Mol Aspects Med 21: 167–223
    1. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, van de Vijver M (2003) Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16: 173–182
    1. Bohl Kullberg E, Bergstrand N, Carlsson J, Edwards K, Johnsson M, Sjoberg S, Gedda L (2002) Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents. Bioconjug Chem 13: 737–743
    1. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I–III breast cancer patients. Cancer Res 61: 1890–1895
    1. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66: 107–117
    1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648
    1. Eccles SA (2002) The role of c-erbB-2/HER2/neu in breast cancer progression and metastases. J Mammary Gland Biol Neoplasia 6: 393–406
    1. Esteva FJ, Sahin AA, Critofanilli M, Arun B, Hortobagyi GN (2002) Molecular prognostic factors for breast cancer metastases and survival. Sem Radiat Oncol 12: 319–328
    1. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13: 1036–1043
    1. Goldenberg DM (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52: 281–296
    1. Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7: 971–994
    1. Kwekkeboom D, Krenning EP, de Jong M (2000) Peptide receptor imaging and therapy. J Nucl Med 41: 1704–1713
    1. Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334–341
    1. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852–1857
    1. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30: 259–265
    1. McKeage K, Perry CM (2002) Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62: 209–243
    1. Niehans GA, Singleton TP, Dykoski D, Kiang DT (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85: 1230–1235
    1. Onyango P (2002) Genomics and cancer. Curr Opin Oncol 14: 79–85
    1. O'Rourke DM, Kao GD, Singh N, Park BW, Muschel RJ, Wu CJ, Greene MI (1998) Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci USA 95: 10842–10847
    1. Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R (2000) Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 18: 194–198
    1. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4: 95–99
    1. Pegram MD, Konecny G, Slamon DJ (2000) The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (Trastuzumab) therapy for cancer. Cancer Treat Res 103: 747–775
    1. Rummukainen JK, Salminen T, Lundin J, Joensuu H, Isola JJ (2001) Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples. Lab Invest 81: 1545–1551
    1. Shimizu C, Fukutomi T, Tsuda H, Akashi-Tanaka S, Watanabe T, Nanasawa T, Sugihara K (2000) C-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73: 17–20
    1. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141–1146
    1. Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstad B, Wist E, Valvere V, Bergh J, Skiold-Petterson D, Saksela E, Blomqvist C (2002) C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 38: 535–542
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
    1. Tanner M, Jarvinen P, Isola J (2001) Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61: 5345–5348
    1. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ, Fruehauf JP (2000) Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 278: 130–136
    1. Thor A (2001) Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? J Natl Cancer Inst 93: 1120–1121
    1. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y (2002) EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur J Surg Oncol 28: 383–387
    1. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X (2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94: 2169–2173
    1. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU (2002) HER-2 – a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41: 282–288
    1. Xu R, Perle MA, Inghirami G, Chan W, Delgado Y, Feiner H (2002) Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15: 116–124
    1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera